Latest news with #Crestor
Associated Press
6 days ago
- Business
- Associated Press
Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia
Grünenthal today announced the acquisition of the commercial rights to Cialis® (tadalafil) in Mexico, Brazil and Colombia from Eli Lilly and Company. Over the next few years, Grünenthal and Lilly will work together to transfer the manufacturing to Grünenthal's production site in Santiago, Chile, that will supply Cialis® for Mexico, Brazil and Colombia moving forward. The transaction is expected to close in the third quarter of 2025, subject to the satisfaction of customary closing conditions. Grünenthal will finance the transaction using available liquidity. The financial terms of the transaction are not disclosed. Cialis® is indicated for the oral treatment of erectile dysfunction and signs and symptoms of benign prostatic hyperplasia in adult men[1]. The acquisition will expand Grünenthal's Latin American Men's Health product portfolio. 'Executing on our strategy of targeted acquisitions, Cialis® will expand our existing portfolio in the region and strengthen Grünenthal's Latin American business', says Gabriel Baertschi, CEO, Grünenthal. 'In 2022, we acquired Nebido®, a long-acting treatment for testosterone deficiency, and with Cialis®we can continue to serve our existing customer base and foster our growth in key Latin American markets.' Through the acquisition of Cialis®, Grünenthal continues executing its strategy of acquiring established medicines to expand its portfolio and increase its profitability. Since 2017, Grünenthal has invested over €2 billion in the acquisition of established medicines, including Nebido®, the European rights to Crestor® and Nexium®, as well as the global rights to Vimovo® (excluding the U.S. and Japan), Qutenza® and Zomig® (excluding Japan). In 2023, Grünenthal established Grünenthal Meds, a joint venture with Kyowa Kirin International, which manages a portfolio of 13 brands primarily focused on pain management and, in 2024, acquired the US company Valinor Pharma and the product Movantik®. About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2024, Grünenthal employed around 4,300 people and achieved revenues of €1.8 billion. More information: Follow us on: LinkedIn:GrunenthalGroup Instagram:grunenthal [1]In Mexico Cialis® is indicated for the oral treatment of erectile dysfunction and symptoms of benign prostatic hyperplasia in adult men.
Forbes
24-04-2025
- Health
- Forbes
How To Cut Pharmacy Costs As Tariffs Push Drug Prices Even Higher
Pharmacy visits can often feel like an expensive necessity. Between prescriptions, over-the-counter medications, and health-related products, the costs can add up quickly — especially as tariffs on pharmaceutical imports begin to impact drug prices. 'Tariffs on pharmaceuticals could increase the price of generic drugs by as much as 17.5%,' according to a report by the Brookings Institution, referring specifically to a proposed 25% tariff on drugs imported from India — a major supplier to the U.S. But even in a climate of rising costs and global trade uncertainty, there are practical ways to reduce your pharmacy bill. Here are expert-backed strategies to help you save money on your next visit to the pharmacy — without sacrificing your health or skipping essential medications. If you haven't tried a prescription discount card like GoodRx, you could be missing out on major savings—without even switching pharmacies. GoodRx lets you compare prices at pharmacies near you and shows you which one offers the lowest price for your medication. In many cases, you can stay at your preferred pharmacy and simply show the GoodRx coupon at checkout to get the discount. The price differences can be shocking. One pharmacy might charge $60 for a medication, while another just a few blocks away sells it for $15. GoodRx helps you cut through that confusion and pay the lowest price available. Other programs like RxSaver and SingleCare work the same way, giving you options and control over what you pay—whether it's a generic or brand-name prescription. Before you refill a prescription, take 60 seconds to check one of these tools. It's one of the easiest ways to stretch your healthcare dollars without sacrificing convenience. Over-the-counter staples like pain relievers, allergy medications, and vitamins might not seem expensive individually — but the cost adds up over time. One easy way to save is by buying in bulk. For products you use often, larger quantities can offer better value and reduce the number of trips to the pharmacy. Just make sure to check expiration dates before stocking up. Pharmacy prices can vary dramatically—even within the same chain. This variation often comes down to local pricing strategies, supplier contracts, and whether the pharmacy accepts discount programs. According to a report by PharmacyChecker, the price for 90 tablets of Crestor 10 mg ranged from $622.69 at a Houston pharmacy to $932.99 at one in Orlando, Florida. That's a difference of more than $300 for the exact same medication. That's why it pays to shop around. For longer-term prescriptions, mail-order pharmacies can sometimes offer a lower monthly cost—another option worth exploring. Pharmaceutical companies often provide coupons and rebates for brand-name drugs, especially for patients who are paying out of pocket. Websites like RxCoupons offer printable coupons that can give you instant savings at the pharmacy. Many drug manufacturers also have patient assistance programs that help people afford their medications. Be sure to check both the manufacturer's website and third-party coupon websites before your next visit. If you have a Health Savings Account (HSA) or a Flexible Spending Account (FSA) through your employer, you can use those funds to pay for eligible prescription medications and certain over-the-counter products. According to IRS Publication 969, these accounts let you set aside pre-tax dollars, which can lower your taxable income and help cover out-of-pocket healthcare costs more efficiently. Both HSAs and FSAs can be used for a wide range of qualified expenses—from prescriptions to allergy meds, pain relievers, and even menstrual care products. Leveraging these accounts for everyday health expenses is one of the easiest ways to stretch your healthcare dollars throughout the year. If you're uninsured or underinsured, there are still ways to save on prescription medications. Many pharmaceutical companies offer patient assistance programs that provide drugs at low or no cost to eligible patients. These programs aren't always widely advertised, so it's worth asking your doctor or pharmacist if you qualify. According to a report by the Congressional Research Service, patient assistance programs are designed to "provide free or discounted prescription drugs to low-income individuals who lack insurance coverage." The programs are typically offered by pharmaceutical manufacturers and are aimed at helping people access costly medications they might not otherwise afford." You can read the full report here. Your provider can help determine which programs are available and may even assist with the application process. Many pharmacies have programs that can save you money by offering lower-cost alternatives to your current prescriptions. With your doctor's approval, a pharmacist might recommend a generic version or a similar medication that's just as effective but far less expensive. If you're taking a pricey medication, don't hesitate to ask your pharmacist if there's a more affordable substitute available — it could make a big difference in your monthly costs. you're on a costly medication, ask your pharmacist if a substitution might be a good option for you. Many pharmacies offer a discount when you buy a 90-day supply of medications instead of filling them every month. A 90-day prescription can be up to 25% cheaper than buying monthly refills, according to the Centers for Medicare and Medicaid Services. If you take a maintenance medication that doesn't change often, consider switching to a 90-day prescription for long-term savings.
The Guardian
13-04-2025
- Health
- The Guardian
Trump is ‘fully fit' and manages high cholesterol, says White House physician
Donald Trump – the oldest person to ever be elected US president – controls high cholesterol with medication and has elevated blood pressure but is 'fully fit', White House physician Sean Barbella said in a report released on Sunday. The US navy captain's report was published two days after Trump underwent a routine physical. It also said he was up to date on all recommended vaccines – despite his national health secretary Robert F Kennedy Jr having spent years sowing doubt about the safety and efficacy of vaccination. Trump himself has previously spread debunked claims about links between vaccines and autism often invoked by Kennedy. Barbella's report is the most detailed information on the health of Trump, 78, since he returned to the White House in January for a second presidency. 'President Trump exhibits excellent cognitive and physical health and is fully fit to execute the duties of the Commander-in-Chief and Head of State,' Barbella wrote in his report. The report noted that Trump's high cholesterol is 'well-controlled' with two medications addressing it. The medicines are rosuvastatin and ezetimibe, generic names of the branded drugs Crestor and Zetia. They have improved Trump's cholesterol over time. Ideally, total cholesterol should be less than 200. At his physical in January 2018, his total cholesterol was 223. In early 2019, the reading came in at 196 and it stood at 167 in 2020. In Sunday's report, it was listed as 140. Trump's blood pressure was 128 over 74. That is considered elevated. And people with elevated blood pressure are likely to develop high blood pressure – or hypertension – unless they take steps to control the condition. The report also noted that Trump has scarring on his right ear, the result of a gunshot wound he suffered when a would-be assassin fired at him during a campaign rally in Pennsylvania last year. A secret service sniper killed the attacker, who fatally shot one spectator while wounding two others. Barbella's report also references Trump's history with Covid-19. Trump was hospitalized during a serious bout with the virus in October 2020 during a run for re-election that ended in defeat to Joe Biden. Amid questions about his age and mental acuity, Biden then dropped out of an electoral rematch with Trump in November 2024 and endorsed his vice-president, Kamala Harris, to succeed him. Trump won the popular and electoral votes against Harris to return to the presidency. Sign up to Headlines US Get the most important US headlines and highlights emailed direct to you every morning after newsletter promotion After the exam preceding the report, Trump told journalists on Air Force One: 'It went, I think, well ... Every test you can imagine, I was there for a long time, the yearly physical. 'I think I did well.' Trump also told reporters he took a cognitive test. Barbella's report gave Trump a 30 out of 30 on what is known as the Montreal Cognitive Assessment. The screening takes about 10 minutes to administer, according to information online. One version available online asks those undergoing the screening to draw a clock, repeat words, name animals and count backwards from 100 at intervals of seven, among other tasks. Trump's resting heart rate was 62 beats per minute, in line with previous tests. A normal resting heart rate for adults ranges from 60 beats to 100 beats per minute. And generally, a lower rate implies better cardiovascular fitness. Reuters and the Associated Press contributed reporting
Yahoo
06-02-2025
- Business
- Yahoo
Seeking Clues to Astrazeneca (AZN) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
In its upcoming report, Astrazeneca (AZN) is predicted by Wall Street analysts to post quarterly earnings of $1.07 per share, reflecting an increase of 46.6% compared to the same period last year. Revenues are forecasted to be $14.28 billion, representing a year-over-year increase of 18.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock. While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights. Bearing this in mind, let's now explore the average estimates of specific Astrazeneca metrics that are commonly monitored and projected by Wall Street analysts. According to the collective judgment of analysts, 'Alliance Revenue- Total' should come in at $615.99 million. The estimate suggests a change of +45.3% year over year. Analysts predict that the 'BioPharmaceuticals- CVRM- Crestor- World' will reach $250.88 million. The estimate indicates a change of +1.6% from the prior-year quarter. Analysts expect 'BioPharmaceuticals- CVRM- Seloken/Toprol-XL- World' to come in at $146.96 million. The estimate suggests a change of +2.1% year over year. The collective assessment of analysts points to an estimated 'Oncology- Zoladex- World' of $260.68 million. The estimate indicates a year-over-year change of +2.6%. The consensus estimate for 'BioPharmaceuticals- CVRM- Crestor- U.S.' stands at $12.07 million. The estimate points to a change of -19.6% from the year-ago quarter. The combined assessment of analysts suggests that 'Other Medicines- Nexium- U.S.' will likely reach $22.59 million. The estimate points to a change of -13.1% from the year-ago quarter. It is projected by analysts that the 'BioPharmaceuticals- R&I- Fasenra- U.S.' will reach $272.75 million. The estimate indicates a change of -0.8% from the prior-year quarter. Based on the collective assessment of analysts, 'BioPharmaceuticals- CVRM- Brilinta- U.S.' should arrive at $166.89 million. The estimate points to a change of -14% from the year-ago quarter. Analysts forecast 'Oncology- Lynparza- U.S.' to reach $357.31 million. The estimate points to a change of +1.5% from the year-ago quarter. The average prediction of analysts places 'Oncology- Imfinzi- U.S.' at $683.59 million. The estimate points to a change of +12.3% from the year-ago quarter. The consensus among analysts is that 'Oncology- Calquence- U.S.' will reach $574.82 million. The estimate points to a change of +20.3% from the year-ago quarter. Analysts' assessment points toward 'BioPharmaceuticals- CVRM- Farxiga- U.S.' reaching $435.80 million. The estimate points to a change of -3.4% from the year-ago all Key Company Metrics for Astrazeneca here>>>Shares of Astrazeneca have demonstrated returns of +6.8% over the past month compared to the Zacks S&P 500 composite's +2.7% change. With a Zacks Rank #3 (Hold), AZN is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report To read this article on click here. Zacks Investment Research Sign in to access your portfolio
